Related Experiment Videos
Interferon-alpha significantly reduces cerebrospinal fluid CD4 cell subsets in HAM/TSP
Juan Feng1, Tatsuro Misu, Kazuo Fujihara
1Department of Neurology, Tohoku University School of Medicine, 1-1 Seiryomachi, Aobaku, 980-8574 Sendai, Japan.
Journal of Neuroimmunology
|September 11, 2003
Summary
Interferon-alpha therapy for human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) reduced CD4+ T cells in cerebrospinal fluid (CSF). Natural killer (NK) and other T cell subsets in CSF remained unchanged.
Area of Science:
- Neuroimmunology
- Virology
- Immunology
Background:
- Human T-lymphotropic virus type 1 (HTLV-1) infection can lead to HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).
- Interferon-alpha (IFN-alpha) is a therapeutic agent used in managing HAM/TSP, but its precise immunomodulatory effects in the central nervous system are not fully understood.
Purpose of the Study:
- To investigate the impact of IFN-alpha treatment on T cell and natural killer (NK) cell subsets within the cerebrospinal fluid (CSF) of HAM/TSP patients.
- To explore potential correlations between changes in CSF lymphocyte subsets and the clinical efficacy of IFN-alpha therapy.
Main Methods:
- Analysis of T cell (CD4+, CD8+) and NK cell subsets in the CSF of nine HAM/TSP patients before and after IFN-alpha treatment.
- Flow cytometry was used to quantify specific cell populations, including CD25+CD4 and CD45RO+CD4 subsets.
Main Results:
- A significant decrease in the CD4/CD8 ratio in CSF post-IFN-alpha therapy was observed.
- This reduction was primarily driven by a significant decrease in CD4+ T cells, particularly CD25+CD4 and CD45RO+CD4 subsets.
- CSF natural T, NK, and NKT cell subsets showed no significant changes following treatment.
Conclusions:
- IFN-alpha therapy in HAM/TSP patients leads to a reduction in specific CD4+ T cell subsets within the CSF.
- Current findings suggest that changes in CSF lymphocyte subsets may not be directly linked to IFN-alpha's clinical efficacy in this patient cohort.
- Further research with larger sample sizes is warranted to confirm these observations and elucidate the immunomodulatory mechanisms of IFN-alpha in HAM/TSP.